Clinical Trials Logo

Clinical Trial Summary

The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients. This study consists of a single blood sample, which will be tested for possible immune abnormalities. If enough patients are found who show immune abnormalities, those patients who are still having uncontrolled seizures will be invited to participate in a study of immune treatment with a compound called intravenous immunoglobulin (IVIG).

The study hypothesis is that a significant proportion of the young-onset, refractory, image-negative, partial-onset epilepsy population have an underlying autoimmune disorder, and many of these patients will respond to immune therapies, including IVIG.

At present, the importance of immune abnormalities in causing epilepsy, and the proper treatment when they are found, are both poorly understood. The investigators hope that this study will help us understand the cause of some cases that are difficult to treat.


Clinical Trial Description

The study is divided into two phases:

Phase I: The investigators will screen for evidence of neuronal nuclear, cytoplasmic, and cell surface autoantibodies in our population of new onset refractory, imaging-negative young adult epilepsy patients. This part of the study involves obtaining a single blood sample, equal to about 2 teaspoons.

Phase 2: If a sufficient number of cases are identified, a double-blind crossover study of IVIG treatment will be performed in these patients. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01545518
Study type Interventional
Source Emory University
Contact
Status Terminated
Phase Phase 2
Start date November 2011
Completion date August 2013

See also
  Status Clinical Trial Phase
Recruiting NCT01450423 - Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy Phase 2
Active, not recruiting NCT03441867 - Neuroimaging Biomarker for Seizures N/A
Terminated NCT03790436 - Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet N/A
Recruiting NCT01762215 - Policy on Optimal Epilepsy Management N/A
Completed NCT01941706 - Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT N/A
Completed NCT00179426 - Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy N/A
Completed NCT00433667 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Completed NCT00425282 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Withdrawn NCT04377425 - COVID-19 Prevalence and Cognitive Deficits in Neurological Patients
Completed NCT03480555 - Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients N/A
Completed NCT03513757 - Dexmedetomidine and Propofol for Pediatric MRI Sedation Phase 4
Not yet recruiting NCT04291716 - Study to Validate Novel Seizure-Detection Algorithm N/A
Recruiting NCT06265103 - Epilepsy Learning Healthcare System (ELHS)
Recruiting NCT03484039 - Incorporating Multidimensional Psychosocial Interventions Improves the Well-being of Individuals With Epilepsy N/A
Active, not recruiting NCT01978470 - External Trigeminal Nerve Stimulation for Drug Resistent Epilepsy N/A
Completed NCT00179517 - Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo Phase 2
Active, not recruiting NCT04553757 - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Recruiting NCT03233399 - Modulating Movement Intention Via Cortical Stimulation N/A
Completed NCT04439656 - Detecting Absence Seizures Using Eye Tracking
Withdrawn NCT04102254 - Thalamic Stimulation for Epilepsy Study N/A